semaglutide weight loss program for Loss: How It Works, Comparisons, and More Unlock Your Weight Loss Potential

Methane, Motility, and GLP-1 Therapy Methane production is associated with slower intestinal transit and constipation-predominant physiology

Dietary changes often accompany GLP-1 treatment, as patients naturally consume smaller portions and may alter their food choices

10.1016/j.ophtha.2024.08.023

Most Common Adverse Events Key Observations: Gastrointestinal adverse events are dose-dependent and most pronounced during dose escalation Symptoms typically peak within the first 4-8 weeks and diminish with continued treatment as tolerance develops Slow titration (4-week intervals) significantly reduces the incidence and severity of GI events Most adverse events classified as mild to moderate in severity [9] Discontinuation Rates 7.3% Placebo discontinuation rate [9] 15.8% Cagrilintide 2.4 mg (optimal dose) [9] 24.5% Cagrilintide 4.5 mg (high dose) [9] The majority of discontinuations due to adverse events occurred during the titration phase, with GI symptoms (nausea, vomiting) being the primary reasons

The entire process should take 5-10 seconds without forcing or hesitation, which can indicate hitting resistance from deeper tissue

Delivery is a weekly injection